regenerative-and-precision-medicine-2016_tracks

3 / 13

Notes:
Page 27
Regenerative & Precision Medicine 2016
December 1-2, 2016
Volume 7, Issue 3(Suppl) J Tissue Sci Eng
ISSN: 2157-7552 JTSE, an open access journal
conferenceseries .com
December 1-2, 2016 | San Antonio, USA
Global Congress on
Tissue Engineering, Regenerative &
Precision Medicine
Hala Gabr et al., J Tissue Sci Eng 2016, 7:3(Suppl)
Autologous stem cell transplantation in patients with idiopathic premature ovarian failure
Hala Gabr, Wael Abo Elkheir and Ahmed El-Gazzar
Cairo University, Egypt
Military Medical Academy, Egypt
Background: Premature ovarian failure (POF) is defined as failure of the ovary to function adequately in its role either as
an endocrine organ or as a reproductive organ in a woman younger than 40 years of age. It is characterized by amenorrhea,
hypoestrogenism and elevated serum gonadotropin levels. This condition occurs in approximately 1% of women and it has
major physical and psychological consequences/impact in those patients. Stem cell therapy is increasingly gaining grounds in
the regeneration of damaged or failed tissues and organs.
Aim: The purpose of this study is to investigate the role of the transplantation of autologous bone marrow derivedmesenchymal
stem cells in amelioration of this condition.
Study Design: It is an open label single group safety/efficacy study. Primary outcome measures are cases will be followed using
serum FSH, estrogen and anti-mullerian hormone levels. Secondary outcome measures are disappearance of menopausal
symptoms e.g., hot flashes rise in serum AMH level, pregnancy rate within 1 year, miscarriage rate within one year of injection
and long term follow-up for any adverse effect, assessed for one year from injection.
Subjects: 30 patients with POF were included. Inclusion Criteria: (1) Patients with normal karyotype spontaneous premature
ovarian failure. (2) Patients between 18-40 years old. Exclusion Criteria: (1) Patients with secondary ovarian failure (e.g.,
hypothalamic causes). (2) Autoimmune diseases. (3) Those with major medical problems such as malignancy, hepatitis, etc and
(4) Abnormal karyotyping (e.g., Turner syndrome)
Methods: After stimulation with G-CSF, 60 ml of bone marrow were aspirated from the posterior iliac spine and mesenchymal
stem cells (MSCs) isolation was done under GMP conditions. Isolated MSCs were injected in one side as follows; 3-5 million
in the ovarian tissue through laparoscope and 3-5 million in the ovarian artery through catheter.
Results & Conclusions: 26 out of the 30 patients included (86.7%) showed fall in FSH levels and rise in estrogen and AMH
levels after 4 weeks of injection and this change was maintained throughout the 48 week follow-up period. 18 patients (60%)
showed ovulation with ovum sizes ranging from 12-20 mm. Only one patient had spontaneous pregnancy, while three patients
were subjected to IVF cycles. This study shows that autologous MSC may improve the conditions in patients with POF.
Optimization of the cell dose and route of injection needs further experimentation.
Biography
Hala Gabr is a renowned Researcher in Stem Cell Biology and Therapy in Cairo University, Egypt. She is the Director of the Pediatric Bone Marrow Transplantation
and Cellular Therapy Lab in Cairo University. She is the Co-Founder of the Egyptian Society for Progenitor Stem Cell Research, the leading stem cell research
body in Egypt. She has published more than 30 papers in reputed journals and is an Editorial Board Member of a number of reputed journals. She has supervised
nearly a hundred PhD and master thesis in stem cell research.